The University of Modena and Reggio Emilia , located in Modena and Reggio Emilia, Emilia-Romagna, Italy, is one of the oldest universities in Italy, founded in 1175, with a population of more than 20,000 students.The medieval university disappeared by 1338 and was replaced by "three public lectureships" which did not award degrees and were suspended in the 1590s "for lack of money". The university was not reestablished in Modena until the 1680s and did not receive an imperial charter until 1685. Wikipedia.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2016 | Award Amount: 1.12M | Year: 2017
The manufacturing industry is entering a new era in which new ICT technologies and collaboration applications are integrated with traditional manufacturing practices and processes, which brings virtual organisations to factories, i.e. Manufacturing 2.0. Virtual factory to future manufacturing slows the flexible amalgamation of manufacturing resources in multiple organisations to create timely, demand driven product lines. The project vF Interoperation suppoRting buSiness innovaTion (FIRST) provides the new technology and methodology to describe manufacturing assets; to compose and integrate the existing services into collaborative virtual manufacturing processes; and to deal with evolution of changes. From the overarching objective to enhance manufacturing integration through the application of advanced IT solutions, the innovative project brings together an experienced researcher with expertise in the designing an interoperability framework for facilitating interoperability on data/information, services and process levels respectively. These outcomes lead to significant business innovations for virtual factories, made possible by an internationally recognised group expertise in (manufacturing) services/assets description languages, semantic services discover methods, and automated interoperability. The experienced researcher has an existing background in service oriented business process management; ontology based process model registration and management; and web service discovery and selection. She combines this with a perspective on application of those technologies. The FIRST project will take advantage of this complementary experience as well as the academic and industrial relationships in Europe and China respectively, taking advantage of the unique opportunity to address the concept from both perspectives.
Agency: European Commission | Branch: H2020 | Program: ECSEL-IA | Phase: ECSEL-17-2015 | Award Amount: 64.82M | Year: 2016
ENABLE-S3 will pave the way for accelerated application of highly automated and autonomous systems in the mobility domains automotive, aerospace, rail and maritime as well as in the health care domain. Virtual testing, verification and coverage-oriented test selection methods will enable validation with reasonable efforts. The resulting validation framework will ensure Europeans Industry competitiveness in the global race of automated systems with an expected market potential of 60B in 2025. Project results will be used to propose standardized validation procedures for highly automated systems (ACPS). The technical objectives addressed are: 1. Provision of a test and validation framework that proves the functionality, safety and security of ACPS with at least 50% less test effort than required in classical testing. 2. Promotion of a new technique for testing of automated systems with physical sensor signal stimuli generators, which will be demonstrated for at least 3 physical stimuli generators. 3. Raising significantly the level of dependability of automated systems due to provision of a holistic test and validation platform and systematic coverage measures, which will reduce the probability of malfunction behavior of automated systems to 10E-9/h. 4. Provision of a validation environment for rapid re-qualification, which will allow reuse of validation scenarios in at least 3 development stages. 5. Establish open standards to speed up the adoption of the new validation tools and methods for ACPS. 6. Enabling safe, secure and functional ACPS across domains. 7. Creation of an eco-system for the validation and verification of automated systems in the European industry. ENABLE-S3 is strongly industry-driven. Realistic and relevant industrial use-cases from smart mobility and smart health will define the requirements to be addressed and assess the benefits of the technological progress.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FCT-01-2015 | Award Amount: 11.99M | Year: 2016
ASGARD has a singular goal, contribute to Law Enforcement Agencies Technological Autonomy and effective use of technology. Technologies will be transferred to end users under an open source scheme focusing on Forensics, Intelligence and Foresight (Intelligence led prevention and anticipation). ASGARD will drive progress in the processing of seized data, availability of massive amounts of data and big data solutions in an ever more connected world. New areas of research will also be addressed. The consortium is configured with LEA end users and practitioners pulling from the Research and Development community who will push transfer of knowledge and innovation. A Community of LEA users is the end point of ASGARD with the technology as a focal point for cooperation (a restricted open source community). In addition to traditional Use Cases and trials, in keeping with open source concepts and continuous integration approaches, ASGARD will use Hackathons to demonstrate its results. Vendor lock-in is addressed whilst also recognising their role and existing investment by LEAs. The project will follow a cyclical approach for early results. Data Set, Data Analytics (multimodal/ multimedia), Data Mining and Visual Analytics are included in the work plan. Technologies will be built under the maxim of It works over Its the best. Rapid adoption/flexible deployment strategies are included. The project includes a licensing and IPR approach coherent with LEA realities and Ethical needs. ASGARD includes a comprehensive approach to Privacy, Ethics, Societal Impact respecting fundamental rights. ASGARD leverages existing trust relationship between LEAs and the research and development industry, and experiential knowledge in FCT research. ASGARD will allow its community of users leverage the benefits of agile methodologies, technology trends and open source approaches that are currently exploited by the general ICT sector and Organised Crime and Terrorist organisations.
Pagnoni G.,University of Modena and Reggio Emilia
Journal of Neuroscience | Year: 2012
Neuroimaging data suggest a link between the spontaneous production of thoughts during wakeful rest and slow fluctuations of activity in the default mode network (DMN), a set of brain regions with high basal metabolism and a major neural hub in the ventral posteromedial cortex (vPMC). Meta-awareness and regulation of mind-wandering are core cognitive components of most contemplative practices and to study their impact on DMN activity, we collected functional MRI (fMRI) data from a cohort of experienced Zen meditators and meditation-naive controls engaging in a basic attention-to-breathing protocol. We observed a significant group difference in the skewness of the fMRI BOLD signal from the vPMC, suggesting that the relative incidence of states of elevated vPMC activity was lower in meditators; furthermore, the same parameter was significantly correlated with performance on a rapid visual information processing (RVIP) test for sustained attention conducted outside the scanner. Finally, a functional connectivity analysis with thevPMCseed revealed a significant association of RVIP performance with the degree of temporal correlation between vPMC and the right temporoparietal junction (TPJ), a region strongly implicated in stimulus-triggered reorienting of attention. Together, these findings suggest that thevPMC BOLD signal skewness and the temporal relationship of vPMC and TPJ activities reflect the dynamic tension between mind-wandering, meta-awareness, and directed attention, and may represent a useful endophenotype for studying individual differences in attentional abilities and the impairment of the latter in specific clinical conditions. © 2012 the authors.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.59M | Year: 2017
Advanced Microscopy techniques are widely recognized as one of the pillars onto which the research and manufacture of Nanotechnology based products is sustained. At present, the greatest challenge faced by these techniques is the realization of fast and non-destructive tomographic images with chemical composition sensitivity and with sub-10 nm spatial resolution, in both organic and inorganic materials, and in all environmental conditions. Scanning Probe Microscopes are currently the Advanced Microscopy techniques experiencing the fastest evolution and innovation towards solving this challenge. Scanning Probe Microscopes have crossed fundamental barriers, and novel systems exist that show potential unparalleled performance in terms of 3D nanoscale imaging capabilities, imaging speed and chemical sensitivity mapping. The objective of the SPM2.0 European Training Network is to train a new generation of researchers in the science and technology of these novel Scanning Probe Microscopes, in which Europe is currently in a leading position, in order to enforce its further development and its quick and wide commercialization and implementation in public and private research centers and industrial and metrology institutions. The researchers of the network will acquire a solid state-of-the-art multidisciplinary scientific training in this field of research, covering from basic science to industrial applications, which should enable them to generate new scientific knowledge of the highest impact. In addition, they will receive a practical training on transferable skills in order to increase their employability perspectives and to qualify them to access to responsibility job positions in the private and public sectors. The final aim of the network is to consolidate Europe as the world leader in Scanning Probe Microscopy technologies and its emerging applications in key sectors like Materials, Microelectronics, Biology and Medicine.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-11-2016-2017 | Award Amount: 6.00M | Year: 2017
Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disability, often requiring biological enhancement. Regenerative medicine research suggests to the general public that alternative treatments based on advanced therapy medicinal products (ATMP) are already available. However, early clinical trials only explore its potential benefit. Underreported results and absence of early trial confirmation in adequately powered prospective randomized clinical trials (RCT) indicate that evidence is not available to transfer any technique into routine clinical application. This ORTHOUNION Project was developed from FP7-Project (REBORNE). Its results confirmed 92% bone healing rate (Gmez-Barrena et al, 2016 submitted manuscript) with an autologous ATMP of GMP expanded bone marrow derived human MSC in non-unions, where the reported bone healing rate after surgery with standard bone autograft is 74%. Any further development requires adequately powered prospective RCTs. This will be the main aim of ORTHOUNION: to assess clinically relevant efficacy of an autologous ATMP with GMP multicentric production in a well-designed, randomized, controlled, three-arm clinical trial under GCP, versus bone autograft, gold-standard in fracture non-unions. A non-inferiority analysis will evaluate if cell dose can be lowered. ATMP has been authorized by the National Competent Authorities of the participating countries in 3 previous trials (REBORNE) and will be monitored by ECRIN-ERIC to ensure quality and credibility of RCT results. Secondary aims include innovative strategies to increase manufacturing capacity and lower costs to pave translation into routine clinical treatments, biomaterial refinement to facilitate surgery, personalized medicine supportive instruments for patient selection and monitoring, and health economic evaluation. Results in this project may help define the future of bone regenerative medicine
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-25-2015 | Award Amount: 4.96M | Year: 2016
The ambition of the CONNECARE consortium is to co-design, develop, deploy, and evaluate a novel smart, adaptive integrated care system for chronic care management. This will save European healthcare organisations huge sums whilst improving patient outcomes. The consortium contains all the necessary partners to ensure success. Based on the concept of 4P medicine, CONNECARE will provide decision support for the adaptive management of personalised clinical pathways and will deliver tools to monitor patients activities and status, thus empowering them and providing them with recommendations to self-manage their condition, resulting in substantial improvements in their quality of life. The three dimensions underpinning the required proposed paradigm shift are: 1. Organisational: making health and social care systems interoperable, promoting collaboration among care settings, and moving from institutional reactive care to a home-based preventive model. 2. Care and social services: addressing health risk prediction by combining already operational population-based tools with a patient-based five-dimension scoring strategy consisting of i) screening, ii) risk stratification, iii) mapping, iv) intervention, and v) surveillance. 3. Technological: delivering a CONNECARE system which leverages existing assets from partners to offer smart Adaptive Case Management, self-management and 3-level monitoring features, fully integrated with management systems in place. An iterative patient-centred co-design process will ensure a progressive refinement of model and tools, providing foundations for adoption and transferability. In addition, clinical trials will be held in three leading-light regions in integrated care uptake Catalonia, Israel, and Groningen to evidence improvements in outcomes and efficiency. Consortium members are active in the EIP AHA B3 Action Group; transfer of results to relevant stakeholders across Europe, beyond the stakeholders in CONNECARE, is guaranteed.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SPIRE-04-2016 | Award Amount: 5.08M | Year: 2016
The DREAM project aims to design, develop and demonstrate a radically improved architecture for ceramic industrial furnaces, characterised by optimised energy consumption, reduced emissions, and lower operating costs compared to currently available technological solutions. This will be obtained by substantially enhancing specific furnace parts (control system, refractories, emissions abatement system) and by adding new modules and sub-systems (CHP unit, heat pipes) to the current furnace architecture. DREAM Specific objectives will be: O1 To design innovative hardware furnace components improving energy efficiency (biofuel-fed CHP unit, heat pipes, emission abatement system) O2 To introduce substantial improvements on current hardware-software kiln parts (kiln control tool, refractory materials) O3 To test the DREAM solutions in a variety of industrial settings (retrofitting and pilot kiln demonstrators) O4 To pave the way for a full seizure of DREAM related market opportunities (dissemination, exploitation within the ceramic sector and market replication) DREAM will develop and demonstrate technologies enabling a significant advancement in the sustainability of ceramics processes, implementing 5 synergic lines of research and 3 industrial demonstrators, which will act as technological showcases for market deployment. Such approach will enable to advance, in the five lines of research, from TRL4 to TRL6. DREAM will strongly contribute to both the sustainability and competitiveness of the European ceramics and process industries. In particular, the DREAM technologies will earn an overall 20% OPEX and energy consumption reduction for industrial furnaces, with an average investment payback time for end users lower than 3 years. The DREAM coordinator and industrial partners are technology and market leaders in the ceramics equipment field, and this will streamline the translation of the DREAM research results into successful products and services.